Dillon & Associates Inc. Buys 6,572 Shares of Danaher Corporation $DHR

Dillon & Associates Inc. boosted its stake in shares of Danaher Corporation (NYSE:DHR) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 54,312 shares of the conglomerate’s stock after buying an additional 6,572 shares during the period. Danaher makes up approximately 1.4% of Dillon & Associates Inc.’s holdings, making the stock its 22nd largest holding. Dillon & Associates Inc.’s holdings in Danaher were worth $10,754,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DHR. WFA of San Diego LLC bought a new position in Danaher in the 2nd quarter worth about $26,000. Howard Hughes Medical Institute purchased a new stake in shares of Danaher during the 2nd quarter worth $27,000. TruNorth Capital Management LLC bought a new position in shares of Danaher during the 3rd quarter worth approximately $28,000. Red Tortoise LLC boosted its position in shares of Danaher by 175.0% in the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after purchasing an additional 98 shares in the last quarter. Finally, Tripletail Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter worth approximately $31,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This trade represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the transaction, the director owned 20,762 shares of the company’s stock, valued at approximately $4,702,593. This represents a 13.71% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Performance

Shares of DHR stock opened at $239.83 on Friday. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company has a market cap of $169.40 billion, a P/E ratio of 49.45, a PEG ratio of 4.23 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $227.79 and a 200 day moving average price of $211.58.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.71 earnings per share. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a $0.32 dividend. The ex-dividend date is Friday, December 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.5%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DHR. Wells Fargo & Company upped their price objective on shares of Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. TD Cowen boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Argus set a $265.00 price target on Danaher in a research note on Wednesday. KeyCorp reiterated an “overweight” rating on shares of Danaher in a report on Thursday, December 18th. Finally, Jefferies Financial Group boosted their price target on shares of Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Twenty-one research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $250.96.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.